中国组织工程研究 ›› 2021, Vol. 25 ›› Issue (8): 1290-1298.doi: 10.3969/j.issn.2095-4344.3039
• 组织构建综述 tissue construction review • 上一篇 下一篇
姬志祥1,2,蓝常贡3
收稿日期:
2020-05-18
修回日期:
2020-05-20
接受日期:
2020-07-09
出版日期:
2021-03-18
发布日期:
2020-12-14
通讯作者:
蓝常贡,硕士,主任医师,教授,右江民族医学院附属医院脊柱外科,广西壮族自治区百色市 533000
作者简介:
姬志祥,男,1994年生,山西省阳城县人,汉族,右江民族医学院在读硕士,主要从事关节炎及痛风的研究。
基金资助:
Ji Zhixiang1, 2, Lan Changgong3
Received:
2020-05-18
Revised:
2020-05-20
Accepted:
2020-07-09
Online:
2021-03-18
Published:
2020-12-14
Contact:
Lan Changgong, Master, Chief physician, Professor, Department of Spinal Surgery, Affiliated Hospital of YouJiang Medical University for Nationalities, Baise 533000, Guangxi Zhuang Autonomous Region, China
About author:
Ji Zhixiang, Master candidate, Clinical School of the Affiliated Hospital of YouJiang Medical University for Nationalities, Baise 533000, Guangxi Zhuang Autonomous Region, China; Graduate School of YouJiang Medical University for Nationalities, Baise 533000, Guangxi Zhuang Autonomous Region, China
Supported by:
摘要:
文题释义:
全基因组关联研究(Genome-Wide Association Studies,GWAS):是指在全基因组层面上,开展多中心、大样本、反复验证的基因与疾病的关联研究,是通过对大规模的群体DNA样本进行全基因组高密度遗传标记(如SNP或CNV等)分型,从而寻找与复杂疾病相关的遗传因素的研究方法,全面揭示疾病发生、发展与治疗相关的遗传基因。
尿酸盐转运蛋白:主要位于肾脏和肠道,负责调节人的血清尿酸水平。如近端小管细胞的基底外侧膜中的GLUT9和顶端膜中的URAT1介导肾尿酸重吸收。部分尿酸盐转运蛋白的变体会增加血清尿酸盐水平和痛风风险,这些蛋白的基因多态性研究和药物相关性研究对于痛风的个体化高效治疗有重要意义。
背景:研究表明,GLUT9、URAT1、NPT1和ABCG2等尿酸盐转运蛋白直接参与人的血清尿酸水平调节,其编码基因的多态性与痛风的发生发展密切相关。因此,尿酸盐转运蛋白的针对性治疗成为一种临床治疗痛风的新思路。
目的:总结近几年尿酸盐转运蛋白在痛风中的多态性表达及与临床药物的相关性研究进展,为进一步探究痛风及高尿酸血症的个性化治疗提供文献和理论基础。
方法:由第一作者以“痛风、尿酸盐转运蛋白、高尿酸血症、基因多态性、治疗”为中文检索词,以“Gout,Urate transporter,Hyperuricemia,Polymorphism,GWAS,Therapy”为英文检索词,通过计算机检索CNKI、万方数据库和PubMed数据,检索出相关文献131篇,根据纳入与排除标准,并进行文献增减,筛选出78篇文献进行汇总、归纳,主要包括尿酸盐转运蛋白在痛风中的基因多态性及痛风药物作用机制与尿酸盐转运蛋白的相关性等内容。
结果与结论:大量研究表明,尿酸盐转运蛋白的多态性与尿酸稳态密切相关,以GLUT9、URAT1、NPT1和ABCG2最为重要。这些蛋白在不同人群中的差异性表达,并且与痛风药物的反应机制密切相关。在未来诊疗中,这些研究结果可以帮助评估高尿酸血症患者有无治疗必要,并帮助痛风患者制定个体化高效的治疗方案。通过激活BCRP增强肠道对尿酸的清除来治疗高尿酸血症可能是一种可行方案。
https://orcid.org/0000-0001-6318-2348 (姬志祥)
中国组织工程研究杂志出版内容重点:组织构建;骨细胞;软骨细胞;细胞培养;成纤维细胞;血管内皮细胞;骨质疏松;组织工程中图分类号:
姬志祥, 蓝常贡. 尿酸盐转运蛋白在痛风中的多态性和治疗相关性[J]. 中国组织工程研究, 2021, 25(8): 1290-1298.
Ji Zhixiang, Lan Changgong. Polymorphism of urate transporter in gout and its correlation with gout treatment[J]. Chinese Journal of Tissue Engineering Research, 2021, 25(8): 1290-1298.
[1] DALBETH N, MERRIMAN TR, STAMP LK. Gout.Lancet. 2016;388(10055): 2039-2052. [2] LIN CY, HSIEH MC, KOR CT, et al. Association and risk factors of chronic kidney disease and incident diabetes: a nationwide population-based cohort study. Diabetologia.2019; 62(3): 438-447. [3] CHRISTENSEN JL, YU W, TAN S, et al. Gout Is Associated With Increased Coronary Artery Calcification and Adverse Cardiovascular Outcomes. JACC Cardiovasc Imaging.2020;13(3): 884-886. [4] TATSUMI Y, ASAYAMA K, MORIMOTO A, et al. Hyperuricemia predicts the risk for developing hypertension independent of alcohol drinking status in men and women: the Saku study. Hypertens Res.2020;43(5): 442-449. [5] OH TR, CHOI HS, KIM CS, et al. Hyperuricemia has increased the risk of progression of chronic kidney disease: propensity score matching analysis from the KNOW-CKD study . Sci Rep.2019; 9(1): 6681. [6] CHEN-XU M, YOKOSE C, RAI SK, et al. Contemporary Prevalence of Gout and Hyperuricemia in the United States and Decadal Trends: The National Health and Nutrition Examination Survey, 2007-2016. Arthritis Rheumatol.2019; 71(6): 991-999. [7] RAI SK, AVINA-ZUBIETA JA, MCCORMICK N, et al. The rising prevalence and incidence of gout in British Columbia, Canada: Population-based trends from 2000 to 2012. Semin Arthritis Rheum.2017; 46(4): 451-456. [8] ZOBBE K, PRIETO-ALHAMBRA D, CORDTZ R, et al. Secular trends in the incidence and prevalence of gout in Denmark from 1995 to 2015: a nationwide register-based study. Rheumatology (Oxford).2019; 58(5): 836-839. [9] BARDIN T, BOUEE S, CLERSON P, et al. Prevalence of Gout in the Adult Population of France. Arthritis Care Res (Hoboken).2016; 68(2): 261-266. [10] DEHLIN M, DRIVELEGKA P, SIGURDARDOTTIR V, et al. Incidence and prevalence of gout in Western Sweden. Arthritis Res Ther.2016;18:164. [11] 陈晓波, 李诺利, 陈樱君,等. 钦州地区痛风和高尿酸血症影响因素流行病学研究 [J]. 检验医学与临床, 2017, 14(23): 3470-3472. [12] 刘新琼, 王晓朋, 关黎清,等. 新疆伊犁哈萨克自治州不同民族中高尿酸血症与痛风患病率及相关危险因素分析[J]. 中华全科医学, 2016,14(7):1186-1188,1192. [13] 谭立夫, 朱君, 严妙娟,等. 惠州市惠阳区2008~2014年痛风和高尿酸血症的流行病学调查[J]. 现代诊断与治疗,2016,27(10): 1919-1920. [14] DALBETH N, CHOI HK, JOOSTEN LAB, et al. Gout. Nat Rev Dis Primers. 2019; 5(1): 69. [15] NAKAYAMA A, NAKAOKA H, YAMAMOTO K, et al. GWAS of clinically defined gout and subtypes identifies multiple susceptibility loci that include urate transporter genes. Ann Rheum Dis.2017;76(5): 869-877. [16] WANG Z, CUI T, CI X, et al. The effect of polymorphism of uric acid transporters on uric acid transport. J Nephrol. 2019; 32(2): 177-187. [17] MATSUO H, YAMAMOTO K, NAKAOKA H, et al. Genome-wide association study of clinically defined gout identifies multiple risk loci and its association with clinical subtypes. Ann Rheum Dis.2016; 75(4): 652-659. [18] MANCIKOVA A, KRYLOV V, HURBA O, et al. Functional analysis of novel allelic variants in URAT1 and GLUT9 causing renal hypouricemia type 1 and 2. Clin Exp Nephrol.2016;20(4):578-584. [19] DINOUR D, GRAY NK, CAMPBELL S, et al. Homozygous SLC2A9 mutations cause severe renal hypouricemia. J Am Soc Nephrol.2010; 21(1): 64-72. [20] KAWAMURA Y, NAKAOKA H, NAKAYAMA A, et al. Genome-wide association study revealed novel loci which aggravate asymptomatic hyperuricaemia into gout. Ann Rheum Dis.2019;78(10): 1430-1437. [21] TU HP, MIN-SHAN KO A, LEE SS, et al. Variants of ALPK1 with ABCG2, SLC2A9, and SLC22A12 increased the positive predictive value for gout. J Hum Genet.2018;63(1):63-70. [22] WRIGLEY R, PHIPPS-GREEN AJ, TOPLESS RK, et al. Pleiotropic effect of the ABCG2 gene in gout: involvement in serum urate levels and progression from hyperuricemia to gout . Arthritis Res Ther.2020; 22(1):45. [23] NARANG RK, VINCENT Z, PHIPPS-GREEN A, et al. Population-specific factors associated with fractional excretion of uric acid. Arthritis Res Ther.2019;21(1):234. [24] DALBETH N, HOUSE ME, GAMBLE GD, et al. Population-specific influence of SLC2A9 genotype on the acute hyperuricaemic response to a fructose load. Ann Rheum Dis.2013;72(11):1868-1873. [25] HE W, PHIPPS-GREEN A, STAMP LK, et al. Population-specific association between ABCG2 variants and tophaceous disease in people with gout. Arthritis Res Ther.2017;19(1):43. [26] CHEN G, SHRINER D, DOUMATEY AP, et al. Refining genome-wide associated loci for serum uric acid in individuals with African ancestry. Hum Mol Genet.2020; 29(3): 506-514. [27] SUN YP, XU FL, YAN DD, et al. Association between SLC2A9 Genetic Variants and Risk of Hyperuricemia in a Uygur Population. Curr Med Sci.2019; 39(2): 243-249. [28] YANG X, XIAO Y, LIU K, et al. Prevalence of hyperuricemia among the Chinese population of the southeast coastal region and association with single nucleotide polymorphisms in urateanion exchanger genes: SLC22A12, ABCG2 and SLC2A9. Mol Med Rep.2018;18(3): 3050-3058. [29] DAS GUPTA E, SAKTHISWARY R, LEE S L, et al. Clinical significance of SLC2A9/GLUT9 rs11722228 polymorphisms in gout. Int J Rheum Dis.2018; 21(3): 705-709. [30] SUMA S, NAITO M, OKADA R, et al. ASSOCIATIONS BETWEEN BODY MASS INDEX AND SERUM URIC ACID LEVELS IN A JAPANESE POPULATION WERE SIGNIFICANTLY MODIFIED BY LRP2 rs2544390. Nagoya J Med Sci.2014;76(3-4): 333-339. [31] RIVERA-PAREDEZ B, MACIAS-KAUFFER L, FERNANDEZ-LOPEZ JC, et al. Influence of Genetic and Non-Genetic Risk Factors for Serum Uric Acid Levels and Hyperuricemia in Mexicans. Nutrients.2019;11(6): 1336. [32] ZHOU Z, WANG K, ZHOU J, et al. Amplicon targeted resequencing for SLC2A9 and SLC22A12 identified novel mutations in hypouricemia subjects. Mol Genet Genomic Med.2019;7(7): e00722. [33] TAN P K, FARRAR J E, GAUCHER E A, et al. Coevolution of URAT1 and Uricase during Primate Evolution: Implications for Serum Urate Homeostasis and Gout. Mol Biol Evol.2016;33(9): 2193-2200. [34] HIGASHINO T, MATSUO H, SAKIYAMA M, et al. Common variant of PDZ domain containing 1 (PDZK1) gene is associated with gout susceptibility: A replication study and meta-analysis in Japanese population.Drug Metab Pharmacokinet.2016; 31(6): 464-466. [35] MISAWA K, HASEGAWA T, MISHIMA E, et al. Contribution of Rare Variants of the SLC22A12 Gene to the Missing Heritability of Serum Urate Levels. Genetics.2020;214(4):1079-1090. [36] TIN A, LI Y, BRODY J A, et al. Large-scale whole-exome sequencing association studies identify rare functional variants influencing serum urate levels. Nat Commun.2018; 9(1): 4228. [37] ZOU Y, DU J, ZHU Y, et al. Associations between the SLC22A12 gene and gout susceptibility: a meta-analysis. Clin Exp Rheumatol.2018; 36(3):442-447. [38] IM SW, CHAE J, SON HY, et al. A population-specific low-frequency variant of SLC22A12 (p.W258*) explains nearby genome-wide association signals for serum uric acid concentrations among Koreans. PLoS One. 2020;15(4):e0231336. [39] CHO SK, KIM S, CHUNG JY, et al. Discovery of URAT1 SNPs and association between serum uric acid levels and URAT1 . BMJ Open. 2015;5(11):e009360. [40] SAKIYAMA M, MATSUO H, SHIMIZU S, et al. The effects of URAT1/SLC22A12 nonfunctional variants, R90H and W258X, on serum uric acid levels and gout/hyperuricemia progression. Sci Rep.2016; 6:20148. [41] LEE HA, PARK BH, PARK EA, et al. Long-term effects of the SLC2A9 G844A and SLC22A12 C246T variants on serum uric acid concentrations in children. BMC Pediatr.2018;18(1): 296. [42] DUONG NT, NGOC NT, THANG NTM, et al. Polymorphisms of ABCG2 and SLC22A12 Genes Associated with Gout Risk in Vietnamese Population. Medicina (Kaunas). 2019;55(1):8. [43] LI M, LI Q, LI C G, et al. Genetic polymorphisms in the PDZK1 gene and susceptibility to gout in male Han Chinese: a case-control study. Int J Clin Exp Med. 2015;8(8):13911-13918. [44] PHIPPS-GREEN AJ, MERRIMAN ME, TOPLESS R, et al. Twenty-eight loci that influence serum urate levels: analysis of association with gout. Ann Rheum Dis.2016;75(1):124-130. [45] IHARADA M, MIYAJI T, FUJIMOTO T, et al. Type 1 sodium-dependent phosphate transporter (SLC17A1 Protein) is a Cl(-)-dependent urate exporter. J Biol Chem.2010;285(34):26107-26113. [46] CHIBA T, MATSUO H, KAWAMURA Y, et al. NPT1/SLC17A1 Is a Renal Urate Exporter in Humans and Its Common Gain-of-Function Variant Decreases the Risk of Renal Underexcretion Gout. Arthritis Rheumatol.2015;67(1):281-287. [47] URANO W,TANIGUCHI A,ANZAI N,et al.Sodium-dependent phosphate cotransporter type 1 sequence polymorphisms in male patients with gout. Ann Rheum Dis. 2010; 69(6): 1232-1234. [48] HOLLIS-MOFFATT JE, PHIPPS-GREEN AJ, CHAPMAN B,et al. The renal urate transporter SLC17A1 locus: confirmation of association with gout. Arthritis Res Ther.2012;14(2): R92. [49] YANG Q, KOTTGEN A, DEHGHAN A, et al. Multiple genetic loci influence serum urate levels and their relationship with gout and cardiovascular disease risk factors. Circ Cardiovasc Genet.2010; 3(6): 523-530. [50] GIANESELLO L, CEOL M, BERTOLDI L, et al. Genetic Analyses in Dent Disease and Characterization of CLCN5 Mutations in Kidney Biopsies . Int J Mol Sci.2020; 21(2):516. [51] TIMMER T, TANCK MWT, HUIS IN ‘T VELD EMJ, et al. Associations between single nucleotide polymorphisms and erythrocyte parameters in humans: A systematic literature review. Mutat Res.2019; 779:58-67. [52] SAKIYAMA M, MATSUO H, NAGAMORI S, et al. Expression of a human NPT1/SLC17A1 missense variant which increases urate export. Nucleosides Nucleotides Nucleic Acids. 2016;35(10-12):536-542. [53] ZHOU Z W, CUI L L, HAN L, et al. Polymorphisms in GCKR, SLC17A1 and SLC22A12 were associated with phenotype gout in Han Chinese males: a case-control study. BMC Med Genet.2015;16:66. [54] ROMAN YM, CULHANE-PERA KA, MENK J,et al. Assessment of genetic polymorphisms associated with hyperuricemia or gout in the Hmong. Per Med.2016;13(5): 429-440. [55] BHATNAGAR V, RICHARD EL, WU W, et al. Analysis of ABCG2 and other urate transporters in uric acid homeostasis in chronic kidney disease: potential role of remote sensing and signaling . Clin Kidney J.2016; 9(3): 444-453. [56] ZHANG K, LI C. ABCG2 gene polymorphism rs2231142 is associated with gout comorbidities but not allopurinol response in primary gout patients of a Chinese Han male population. Hereditas.2019;156:26. [57] ROMAN Y, TIIRIKAINEN M, PROM-WORMLEY E. The prevalence of the gout-associated polymorphism rs2231142 G>T in ABCG2 in a pregnant female Filipino cohort. Clin Rheumatol. 2020;39(8):2387-2392. [58] NAKASHIMA A, ICHIDA K, OHKIDO I, et al. Dysfunctional ABCG2 gene polymorphisms are associated with serum uric acid levels and all-cause mortality in hemodialysis patients. Hum Cell. 2020 ;33(3): 559-568. [59] TAKADA T, YAMAMOTO T, MATSUO H, et al. Identification of ABCG2 as an Exporter of Uremic Toxin Indoxyl Sulfate in Mice and as a Crucial Factor Influencing CKD Progression. Sci Rep.2018; 8(1):11147. [60] DALBETH N, STAMP LK, MERRIMAN TR. The genetics of gout: towards personalised medicine?. BMC Med.2017;15(1):108. [61] RISTIC B, SIKDER MOF, BHUTIA YD, et al. Pharmacologic inducers of the uric acid exporter ABCG2 as potential drugs for treatment of gouty arthritis. Asian J Pharm Sci.2020;15(2):173-180. [62] LI G, HAN L, MA R, et al. Glucocorticoids Increase Renal Excretion of Urate in Mice by Downregulating Urate Transporter 1. Drug Metab Dispos. 2019;47(11):1343-1351. [63] OTANI N, OUCHI M, KUDO H, et al. Recent approaches to gout drug discovery: an update. Expert Opin Drug Discov. 2020;15(8):943-954. [64] GRAHAM GG, STOCKER SL, KANNANGARA DRW, et al. Predicting Response or Non-response to Urate-Lowering Therapy in Patients with Gout. Curr Rheumatol Rep.2018; 20(8):47. [65] ROBERTS RL, WALLACE MC, PHIPPS-GREEN AJ, et al. ABCG2 loss-of-function polymorphism predicts poor response to allopurinol in patients with gout. Pharmacogenomics J. 2017;17(2):201-203. [66] WALLACE MC, ROBERTS RL, NANAVATI P, et al. Association between ABCG2 rs2231142 and poor response to allopurinol: replication and meta-analysis. Rheumatology (Oxford).2018; 57(4): 656-660. [67] LIN M, LIU J, ZHOU H, et al. Effects of UDP-glucuronosyltransferase (UGT) polymorphisms on the pharmacokinetics of febuxostat in healthy Chinese volunteers. Drug Metab Pharmacokinet. 2017; 32(1): 77-84. [68] MINER JN, TAN PK, HYNDMAN D, et al. Lesinurad, a novel, oral compound for gout, acts to decrease serum uric acid through inhibition of urate transporters in the kidney. Arthritis Res Ther.2016; 18(1): 214. [69] YANG C, ZHOU D, SHEN Z, et al. Characterization of Stereoselective Metabolism, Inhibitory Effect on Uric Acid Uptake Transporters, and Pharmacokinetics of Lesinurad Atropisomers. Drug Metab Dispos. 2019;47(2): 104-113. [70] ALGHAMDI Y S, SOLIMAN M M, NASSAN M A. Impact of Lesinurad and allopurinol on experimental Hyperuricemia in mice: biochemical, molecular and Immunohistochemical study. BMC Pharmacol Toxicol. 2020;21(1): 10. [71] HOSOYA T, FURUNO K, KANDA S. A clinical pharmacology study of the novel, selective urate reabsorption inhibitor dotinurad in outpatients. Clin Exp Nephrol.2020;24(Suppl 1): 103-111. [72] HOSOYA T, FURUNO K, KANDA S. A non-inferiority study of the novel selective urate reabsorption inhibitor dotinurad versus febuxostat in hyperuricemic patients with or without gout. Clin Exp Nephrol.2020;24(Suppl 1):71-79. [73] LEE Y S, KIM S H, YUK H J, et al. DKB114, A Mixture of Chrysanthemum Indicum Linne Flower and Cinnamomum Cassia (L.) J. Presl Bark Extracts, Improves Hyperuricemia through Inhibition of Xanthine Oxidase Activity and Increasing Urine Excretion. Nutrients.2018;10(10): [74] LIN Y, LIU P G, LIANG W Q, et al. Luteolin-4’-O-glucoside and its aglycone, two major flavones of Gnaphalium affine D. Don, resist hyperuricemia and acute gouty arthritis activity in animal models. Phytomedicine.2018;41:54-61. [75] TASHIRO Y, SAKAI R, HIROSE-SUGIURA T, et al. Effects of Osthol Isolated from Cnidium monnieri Fruit on Urate Transporter 1. Molecules. 2018; 23(11):2837. [76] LEE SH, LEE HS, PARK G, et al. Dual actions on gout flare and acute kidney injury along with enhanced renal transporter activities by Yokuininto, a Kampo medicine . BMC Complement Altern Med. 2019; 19(1): 57. [77] LEE Y S, SUNG Y Y, YUK H J, et al. Anti-hyperuricemic effect of Alpinia oxyphylla seed extract by enhancing uric acid excretion in the kidney. Phytomedicine.2019; 62:152975. [78] WANG S, FANG Y, YU X, et al. The flavonoid-rich fraction from rhizomes of Smilax glabra Roxb. ameliorates renal oxidative stress and inflammation in uric acid nephropathy rats through promoting uric acid excretion.Biomed Pharmacother.2019; 111:162-168. |
[1] | 蒲 锐, 陈子扬, 袁凌燕. 不同细胞来源外泌体保护心脏的特点与效应[J]. 中国组织工程研究, 2021, 25(在线): 1-. |
[2] | 张 超, 吕 欣. 髋臼骨折固定后的异位骨化:危险因素、预防及其治疗进展[J]. 中国组织工程研究, 2021, 25(9): 1434-1439. |
[3] | 周继辉, 李新志, 周 游, 黄 卫, 陈文瑶. 髌骨骨折修复内植物选择的多重问题[J]. 中国组织工程研究, 2021, 25(9): 1440-1445. |
[4] | 王德斌, 毕郑刚. 尺骨鹰嘴骨折-脱位解剖力学、损伤特点、固定修复及3D技术应用的相关问题[J]. 中国组织工程研究, 2021, 25(9): 1446-1451. |
[5] | 袁 美, 张新新, 郭祎莎, 毕 霞. 循环microRNA在血管性认知障碍诊断中的应用[J]. 中国组织工程研究, 2021, 25(8): 1299-1304. |
[6] | 汪显耀, 关亚琳, 刘忠山. 提高间充质干细胞治疗难愈性创面的策略[J]. 中国组织工程研究, 2021, 25(7): 1081-1087. |
[7] | 万 然, 史 旭, 刘京松, 王岩松. 间充质干细胞分泌组治疗脊髓损伤的研究进展[J]. 中国组织工程研究, 2021, 25(7): 1088-1095. |
[8] | 廖成成, 安家兴, 谭张雪, 王 倩, 刘建国. 口腔鳞状细胞癌干细胞的治疗靶点及应用前景[J]. 中国组织工程研究, 2021, 25(7): 1096-1103. |
[9] | 赵 敏, 冯柳祥, 陈 垚, 顾 霞, 王平义, 李一梅, 李文华. 低氧环境下外泌体可作为疾病的标志物[J]. 中国组织工程研究, 2021, 25(7): 1104-1108. |
[10] | 谢文佳, 夏天娇, 周卿云, 刘羽佳, 顾小萍. 小胶质细胞介导神经元损伤在神经退行性疾病中的作用[J]. 中国组织工程研究, 2021, 25(7): 1109-1115. |
[11] | 李珊珊, 郭笑霄, 尤 冉, 杨秀芬, 赵 露, 陈 曦, 王艳玲. 感光细胞替代治疗视网膜变性疾病[J]. 中国组织工程研究, 2021, 25(7): 1116-1121. |
[12] | 焦 慧, 张一宁, 宋雨晴, 林 宇, 王秀丽. 乳腺癌类器官研究进展及临床应用前景[J]. 中国组织工程研究, 2021, 25(7): 1122-1128. |
[13] | 王诗琦, 张金生. 中医药调控缺血缺氧微环境对骨髓间充质干细胞增殖、分化及衰老的影响[J]. 中国组织工程研究, 2021, 25(7): 1129-1134. |
[14] | 曾燕华, 郝延磊. 许旺细胞体外培养及纯化的系统性综述[J]. 中国组织工程研究, 2021, 25(7): 1135-1141. |
[15] | 宋成杰, 常恒瑞, 石明鑫, 孟宪中. 侧方入路腰椎融合治疗后的生物力学稳定性的研究与进展[J]. 中国组织工程研究, 2021, 25(6): 923-928. |
文题释义:#br# 全基因组关联研究(Genome-Wide Association Studies,GWAS):是指在全基因组层面上,开展多中心、大样本、反复验证的基因与疾病的关联研究,是通过对大规模的群体DNA样本进行全基因组高密度遗传标记(如SNP或CNV等)分型,从而寻找与复杂疾病相关的遗传因素的研究方法,全面揭示疾病发生、发展与治疗相关的遗传基因。#br# 尿酸盐转运蛋白:主要位于肾脏和肠道,负责调节人的血清尿酸水平。如近端小管细胞的基底外侧膜中的GLUT9和顶端膜中的URAT1介导肾尿酸重吸收。部分尿酸盐转运蛋白的变体会增加血清尿酸盐水平和痛风风险,这些蛋白的基因多态性研究和药物相关性研究对于痛风的个体化高效治疗有重要意义。
中国组织工程研究杂志出版内容重点:组织构建;骨细胞;软骨细胞;细胞培养;成纤维细胞;血管内皮细胞;骨质疏松;组织工程痛风是一组遗传性或获得性嘌呤代谢紊乱和(或)尿酸排泄障碍所致的综合征,临床表现主要是关节部位出现的疼痛、水肿、红肿和炎症。痛风主要病理学特征是在尿酸浓度逐渐升高的条件下尿酸钠结晶的慢性沉积,单钠尿酸盐沉积的形成依赖高尿酸血症,而血清尿酸盐浓度的升高受到环境因素及遗传因素的影响,且后者更为重要,直接影响了肠道和肾脏对尿酸的代谢过程。高尿酸血症患者是否会出现痛风以及最佳治疗方案仍需进一步研究。
中国组织工程研究杂志出版内容重点:组织构建;骨细胞;软骨细胞;细胞培养;成纤维细胞;血管内皮细胞;骨质疏松;组织工程#br#
阅读次数 | ||||||
全文 |
|
|||||
摘要 |
|
|||||